21st Symposium on Medicinal Chemistry in Eastern England
Thursday 29th April 2010, Fielder Centre, University of Hertfordshire

Organising Committee: Dr A Faller (Eli Lilly), Dr N Hamblin (GlaxoSmithKline)

MORNING PROGRAMME
Chairman: Dr Alan Brown (Pfizer)

The Discovery and Synthesis of a Series of Octahydropyrrolo[3,4-c] pyrrole Based Selective Histamine H4 Receptor Antagonists
Charlotte Lane (Pfizer)

Selective Muscarinic M1 Agonists: A Novel Treatment for Cognitive Disorders
Dale Johnson (GlaxoSmithKline)

Medchem, Metrics and Meaning: Assessing Medicinal Chemistry Progress and Quality in Cancer Drug Discovery Projects
Rob Bradbury (Astra Zeneca)

AFTERNOON PROGRAMME
Chairman: Prof Robin Ganellin (University College London)

Capps-Green-Zamoya Award Presentation

Discovery of Small Molecule Inhibitors of Fatty Acid Amide Hydrolase
Stephen Roughley (Vernalis)

Sitting on a Goldmine: Knowledge Based Design of 5-HT2b Antagonists
David Hirst (GlaxoSmithKline)

Optimum Lipophilicity and Compound Quality -Strategies and Consequences for Lead Optimisation
Mike Waring (AstraZeneca)

HSP 90 - From Fragment to Clinic
Gianni Chessari (Astex)

For further information contact:
Dr A.Faller
Eli Lilly & Co Ltd, Lilly Research Centre,
Erl Wood Manor,
Sunninghill Rd,
Windlesham,
Surrey, GU20 6PH
Tel: 01276 483036. e-mail: faller_andrew@Lilly.com